• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

    2/14/22 4:33:25 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email
    SC 13G/A 1 a020822a.htm SCHEDULE 13G (AMENDMENT #2)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    (Name of Issuer)
    Acorda Therapeutics, Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.001 Per Share

    (CUSIP Number)

    00484M601
    (Date of Event Which Requires Filing of this Statement)
    December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 00484M601
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              464,276 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       464,276 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    464,276 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 00484M601
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              464,276 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       464,276 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    464,276 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 00484M601
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              464,276 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       464,276 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    464,276 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 4.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     


    Item 1(a) Name of issuer:
    Acorda Therapeutics, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    420 Saw Mill River Road, Ardsley, New York 10502
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.001 per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management and Point72 Capital Advisors
    Inc
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.001 Per Share
    2(e) CUSIP Number:
    00484M601

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 464,276
    (b) Percent of class: 4.1% 
    (c) Number of shares as to which the person had:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 464,276 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 464,276

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 464,276
    (b) Percent of class: 4.1% 
    (c) Number of shares as to which the person had:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 464,276 
    (iii) Sole power to dispose or to direct the disposition of: 0 
    (iv) Shared power to dispose or to direct the disposition of: 464,276

    3. Steven A. Cohen
    (a) Amount beneficially owned: 464,276
    (b) Percent of class: 4.1% 
    (c) Number of shares as to which the person had:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 903,364 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 464,276
    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen
    own directly no Shares. Pursuant to an investment management agreement,
    Point72 Asset Management maintains investment and voting power with
    respect to the securities held by certain investment funds it manages. Point72
    Capital Advisors Inc. is the general partner of Point72 Asset Management.
    Mr. Cohen controls each of Point72 Asset Management and Point72 Capital
    Advisors Inc. As of December 31, 2021, by reason of the provisions of
    Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of
    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen
    may be deemed to have beneficially owned 464,276 Shares (constituting
    approximately 4.1% of the Shares outstanding). Each of Point72 Asset
    Management, Point72 Capital Advisors Inc., and Mr. Cohen disclaims
    beneficial ownership of any of the securities covered by this statement.
    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 14, 2022

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $ACOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Burns Thomas M.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:59:21 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Burns Thomas M.

      3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:57:11 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Varian John

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:38:37 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - Acorda Therapeutics, Inc. (0001008848) (Subject)

      5/10/23 4:37:39 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      3/10/23 4:15:17 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      2/14/23 4:52:06 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Acorda Therapeutics Inc.

      10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)

      5/14/24 8:24:14 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)

      10-K/A - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/29/24 8:39:11 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/25/24 8:00:48 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acorda Therapeutics Announces Delisting from Nasdaq

      Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders' equity of at least $10 million. Trading in the Company's common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company's common stock is quoted on the OTC Pink® Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the "ACORQ" ticker symbol. About Acorda Therap

      4/15/24 5:03:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Announces Nasdaq Delisting Notification

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company. In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Nasdaq commenced proceedings to delist the Company's common stock, based on th

      4/3/24 5:30:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

      Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine) to Continue Uninterrupted Acorda Therapeutics, Inc. (NASDAQ:ACOR) ("Acorda" or "the Company") today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million. Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, hea

      4/1/24 6:35:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acorda Therapeutics Announces Resignation of Chief Operating Officer

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been

      8/19/22 8:00:00 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACOR
    Financials

    Live finance-specific insights

    See more
    • Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

      6/17/21 6:09:07 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor

      4/1/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be

      3/25/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Reports Third Quarter 2023 Financial Results

      INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o

      11/13/23 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care